In this study, we referred to the advantages of TBE-NPs in brain delivery and constructed TMZ16e-based anti-EphA3-modified NPs, aiming to deliver TMZ16e to GBM efficiently and overcome the challenges of drug-resistant glioma treatment. The gene discussed is EPHA3; the disease is glioblastoma.